Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 18/20 | 0.63 |
| ▸ | P2RY6 | Q15077 | 13/20 | 0.63 |
| ▸ | P2RY4 | P51582 | 12/20 | 0.63 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2352660 | 1.00 | P2RY2 (0.63) | P2RY2P2RY6P2RY4P2RY14 | |
| Uridine SCHEMBL338288 | 0.91 | P2RY2 (0.65) | P2RY2P2RY6P2RY4P2RY14 | |
| Uridine SCHEMBL5875823 | 0.91 | P2RY2 (0.65) | P2RY2P2RY6P2RY4P2RY14 | |
| Uridine SCHEMBL5875869 | 0.91 | P2RY2 (0.65) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL5068300 | 0.84 | P2RY2 (0.63) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL622267 | 0.82 | P2RY2 (0.62) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL622268 | 0.82 | P2RY2 (0.62) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL14765539 | 0.81 | P2RY2 (0.94) | P2RY2P2RY6P2RY4P2RY14 | |
| Triphosphate SCHEMBL17894276 | 0.81 | P2RY2 (0.94) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL21418854 | 0.81 | P2RY2 (0.94) | P2RY2P2RY6P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4531867-B2 | — | — | 2010-08-25 | — | — | JP | claimed |
| EP-1003474-B1 | METHOD OF TREATING DRY EYE DISEASE WITH PURINERGIC RECEPTOR AGONISTS | INSPIRE PHARMACEUTICALS INC (US) | 2009-04-15 | — | — | EP | claimed |
| EP-1450820-A4 | METHOD FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | INSPIRE PHARMACEUTICALS INC (US) | 2009-02-18 | — | — | EP | claimed |
| US-7256183-B2 | Method for treating or preventing inflammatory diseases | INSPIRE PHARMACEUTICALS, INC. (US) | 2007-08-14 | — | — | US | claimed |
| US-7109181-B2 | Joint lubrication with P2Y purinergic receptor agonists | INSPIRE PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | claimed |
| EP-1450820-A2 | METHOD FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | Inspire Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| US-6596725-B2 | Vision defects | INSPIRE PHARMACEUTICALS, INC. | 2003-07-22 | — | — | US | claimed |
| US-20030125299-A1 | Method for treating or preventing inflammatory diseases | PETERSON WARD M (US) | 2003-07-03 | — | — | US | claimed |
| WO-2003039473-A2 | METHOD FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | INSPIRE PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| US-20030027785-A1 | Joint lubrication with P2Y purinergic receptor agonists | INSPIRE PHARMACEUTICALS, INC. | 2003-02-06 | — | — | US | claimed |
| EP-0981534-A2 | DINUCLEOTIDES AND THEIR USES | Inspire Pharmaceuticals, Inc. (US) | 2000-03-01 | — | — | EP | claimed |
| WO-1998034942-A2 | DINUCLEOTIDES AND THEIR USE | INSPIRE PHARMACEUTICALS, INC. (US) | 1998-08-13 | — | — | WO | claimed |
| US-8008274-B2 | P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20090306010-A1 | P1-(2'-DEOXYCYTIDINE 5'-)P4-(URIDINE 5'-)TETRAPHOSPHATE, TETRA-(ALKALI METAL) SALT, FOR TREATING DISORDERS | MERCK SHARP & DOHME CORP. | 2009-12-10 | — | — | US | disclosed |
| US-7531525-B2 | P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating cystic fibrosis | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1450820-A4 | METHOD FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | INSPIRE PHARMACEUTICALS INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20040077585-A1 | Method of treating edematous retinal disorders | MERCK SHARP & DOHME LLC | 2004-04-22 | — | — | US | disclosed |
| US-20030186917-A1 | Method of treating edematous retinal disorders | MERCK SHARP & DOHME CORP. | 2003-10-02 | — | — | US | disclosed |
| US-20030125299-A1 | Method for treating or preventing inflammatory diseases | PETERSON WARD M (US) | 2003-07-03 | — | — | US | disclosed |
| WO-2003039473-A2 | METHOD FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | INSPIRE PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077585-A1 | Method of treating edematous retinal disorders | P2RY1, P2RY11, P2RY2 | P2RY2 3/4885P2RY6 4/4885P2RY4 5/4885 |
| US-20030125299-A1 | Method for treating or preventing inflammatory diseases | ADORA2B, ADORA2A, P2RY2 | P2RY2 3/4885P2RY6 23/4885P2RY4 20/4885 |
| US-20030186917-A1 | Method of treating edematous retinal disorders | P2RY1, P2RY11, P2RY2 | P2RY2 3/4885P2RY6 4/4885P2RY4 5/4885 |
| US-20030027785-A1 | Joint lubrication with P2Y purinergic receptor agonists | P2RY1, P2RY2, P2RY6 | P2RY2 2/4885P2RY6 3/4885P2RY4 5/4885 |
| US-20090306010-A1 | P1-(2'-DEOXYCYTIDINE 5'-)P4-(URIDINE 5'-)TETRAPHOSPHATE, TETRA-(ALKALI METAL) SALT, FOR TREATING DISORDERS | P2RY1, P2RY4, P2RY2 | P2RY2 3/4885P2RY6 4/4885P2RY4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.